Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics

AFN-1252, a potent enoyl-ACP reductase (FabI) inhibitor, is under development for the treatment of Staphylococcus aureus infections. The activity of AFN-1252 against two isolates of S. aureus, MSSA 26213 and MRSA S186, was studied in an in vitro pharmacodynamic model simulating AFN-1252 pharmacokine...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuji, Brian T, Harigaya, Yoriko, Lesse, Alan J, Forrest, Alan, Ngo, Dung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Maney Publishing 2013
Materias:
Antimicrobial Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558987/
https://www.ncbi.nlm.nih.gov/pubmed/23433442
http://dx.doi.org/10.1179/1973947812Y.0000000060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558987/
https://www.ncbi.nlm.nih.gov/pubmed/23433442
http://dx.doi.org/10.1179/1973947812Y.0000000060

Ejemplares similares